Investigation of the release behavior of a covered-rod-type formulation using silicone

Maeda, Hiroo; Ohashi, Erika; Sano, Akihiko; Kawasaki, Hiromu; Kurosaki, Yuji

doi:10.1016/s0168-3659(03)00158-5

Cited by 15 publications

(17 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[172–174]. However, PDMS is also highly hydrophobic, causing it to absorb hydrophobic drugs, therefore it has been certified as a drug release vehicle in many studies [172–174]. This absorption capability is problematic for in vitro drug testing applications.…”

Section: Applications Of Cardiac Tissue Engineering In Disease Modementioning

confidence: 99%

Biomaterial based cardiac tissue engineering and its applications

Huyer¹,

Montgomery²,

Zhao³

et al. 2015

Biomed. Mater.

View full text Add to dashboard Cite

Cardiovascular disease is a leading cause of death worldwide, necessitating the development of effective treatment strategies. A myocardial infarction involves the blockage of a coronary artery leading to depletion of nutrient and oxygen supply to cardiomyocytes and massive cell death in a region of the myocardium. Cardiac tissue engineering is the growth of functional cardiac tissue in vitro on biomaterial scaffolds for regenerative medicine application. This strategy relies on the optimization of the complex relationship between cell networks and biomaterial properties. In this review, we discuss important biomaterial properties for cardiac tissue engineering applications, such as elasticity, degradation, and induced host response, and their relationship to engineered cardiac cell environments. With these properties in mind, we also emphasize in vitro use of cardiac tissues for high-throughput drug screening and disease modelling.

show abstract

Section: Applications Of Cardiac Tissue Engineering In Disease Modementioning

confidence: 99%

Biomaterial based cardiac tissue engineering and its applications

Huyer¹,

Montgomery²,

Zhao³

et al. 2015

Biomed. Mater.

View full text Add to dashboard Cite

show abstract

“…Sucrose was used as additive and encapsulated along with BSA in the implants. Again, the release was very tunable in these systems 113 . In another study, matrix type and covered rod type injectable implants were compared to deliver protein using either the model antigen avidin or clostridium tetani and clostridium novyi toxoids in sheep 114 .…”

Section: Miscellaneous Modes Of Protein Deliverymentioning

confidence: 88%

“…Tumor suppression was observeed for more than 100 days 111 . Maeda H et al also developed covered-rod-type formulation with silicone polymer to investigate controlled release of small and protein (BSA) molecules 113 . Sucrose was used as additive and encapsulated along with BSA in the implants.…”

Section: Miscellaneous Modes Of Protein Deliverymentioning

confidence: 99%

Long-term delivery of protein therapeutics

Vaishya

Khurana

Patel

et al. 2014

Expert Opinion on Drug Delivery

167

104

View full text Add to dashboard Cite

Introduction Proteins are effective biotherapetics with applications in diverse ailments. Despite being specific and potent, their full clinical potential has not yet been realized. This can be attributed to short half-lives, complex structures, poor in vivo stability, low permeability frequent parenteral administrations and poor adherence to treatment in chronic diseases. A sustained release system, providing controlled release of proteins, may overcome many of these limitations. Areas covered This review focuses on recent development in approaches, especially polymer-based formulations, which can provide therapeutic levels of proteins over extended periods. Advances in particulate, gel based formulations and novel approaches for extended protein delivery are discussed. Emphasis is placed on dosage form, method of preparation, mechanism of release and stability of biotherapeutics. Expert opinion Substantial advancements have been made in the field of extended protein delivery via various polymer-based formulations over last decade despite the unique delivery-related challenges posed by protein biologics. A number of injectable sustained-release formulations have reached market. However, therapeutic application of proteins is still hampered by delivery related issues. A large number of protein molecules are under clinical trials and hence there is an urgent need to develop new methods to deliver these highly potent biologics.

show abstract

“…The excipient-modified silicone elastomer rods were based on implantable matrix and covered-rod formulations described previously in the literature [34][35][36][37][38]. The directly compressed tablets represent the most common and inexpensive drug dosage form, with widespread use for oral administration and occasionally used vaginally.…”

Section: Discussionmentioning

confidence: 99%

“…Vaginal administration of a buffer solution containing the broadly neutralizing human monoclonal antibody b12 has been shown to protect macaques against infection following vaginal challenge with simian-human immunodeficiency virus (SHIV) [37]. Combinations of the monoclonal antibodies 4E10, 2F5 and 2G12, each having broad cross-clade neutralizing properties and relatively conserved binding epitopes, are also being investigated as vaginal HIV microbicides in gel formulations [26].…”

Section: Discussionmentioning

confidence: 99%

Sustained release of proteins from a modified vaginal ring device

Morrow

Woolfson

Donnelly

et al. 2011

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

A new vaginal ring technology, the insert vaginal ring (InVR), is presented. The InVR overcomes the current shortfall of conventional vaginal rings (VRs) that are generally ineffectual for the delivery of hydrophilic and/or macromolecular actives, including peptides, proteins and antibodies, due to their poor permeation characteristics in the hydrophobic polymeric elastomers from which VRs are usually fabricated. Release of the model protein BSA from a variety of insert matrices for the InVR is demonstrated, including modified silicone rods, directly compressed tablets and lyophilised gels, which collectively provided controlled release profiles from several hours to beyond 4 weeks. Furthermore, the InVR was shown to deliver over 1 mg of the monoclonal antibody 2F5 from a single device, offering a potential means of protecting women against the transmission of HIV.

show abstract

Investigation of the release behavior of a covered-rod-type formulation using silicone

Cited by 15 publications

References 12 publications

Biomaterial based cardiac tissue engineering and its applications

Biomaterial based cardiac tissue engineering and its applications

Long-term delivery of protein therapeutics

Sustained release of proteins from a modified vaginal ring device

Contact Info

Product

Resources

About